Eisai Sues Mylan Over Aciphex ANDA

Law360, New York (January 30, 2004, 12:00 AM EST) -- Japanese pharmaceutical company Eisai has filed a lawsuit in the U.S. District Court for the Southern District of New York against generics maker Mylan Laboratories over its abbreviated new drug application for a generic version of ulcer medicine Aciphex.

Eisai said its rabeprazole composition of matter patent is valid until its expiration date of May 8, 2013.

In November, Eisai sued Indian generics maker Dr. Reddy's and Israeli generics marker Teva in the same court for patent infringement over their ANDA application for an Aciphex equivalent....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.